Cla

Quick links to important sections

Cla

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cla

The following description pertains to the pharmaceutical entity Cla, used here as a concise reference for the Fixed-Dose Combination (FDC) preparation containing Amoxicillin, Clarithromycin, and Clavulanic Acid.

Property Description
Active Ingredients Amoxicillin, Clarithromycin, Clavulanic Acid
Form Oral Tablet or Capsule
Pharmacological Class Antibiotic/Antimicrobial Combination Regimen
General Purpose Bacterial Infection Eradication
Origin Semi-synthetic

What Type of Medicine is Cla? The Definitional Framework

Cla is defined as a specialized Combination Antimicrobial Preparation, officially classified within the Antibiotic/Antimicrobial Combination Regimen class. This formulation is designed as an oral preparation, most commonly manufactured as a tablet or capsule, and is derived from semi-synthetic origins, combining chemically altered compounds. As a Fixed-Dose Combination (FDC), this specific multi-drug system is clinically recognized for its role in specific eradication therapies, representing a targeted approach against persistent or resistant bacterial challenges. The triple-drug FDC structure itself is a differentiating factor, as it bundles agents that are often prescribed separately, enhancing patient adherence compared to multi-pill regimens.


The Triple-Agent Composition and Purpose

The preparation utilizes a unique triple composition featuring two distinct antibiotics and one protective agent: the penicillin derivative Amoxicillin, the macrolide Clarithromycin, and the beta-lactamase inhibitor Clavulanic Acid. This specific grouping establishes a broad and powerful front against pathogens, a strategy where combination therapies are utilized to enhance efficacy. Combining antibiotics with different mechanisms is an established method to maximize the successful clearing of infectious disease. The general therapeutic purpose of combining these agents is to efficiently eradicate specific pathogenic bacteria, particularly those suspected of possessing resistance mechanisms, a typical use scenario being where multiple agents are required to overcome the bacterial defense mechanisms.


Why Use a Three-Component Antimicrobial?

This three-component approach is employed to generate a robust synergistic antimicrobial effect, where the total therapeutic impact exceeds the sum of the individual components. Pharmacological studies confirm this rational design strategy actively prevents the deactivation of Amoxicillin by the beta-lactamase enzyme often produced by resistant bacteria. The formulation combines two different methods of bacterial attack—disruption of the cell wall and inhibition of protein synthesis—while the crucial third ingredient, Clavulanic Acid, works to shield the antibiotic. This strategic combination is key to providing a decisive initial therapeutic response to the clinical challenge of antimicrobial resistance.

Regulatory References

  1. WHO AWaRe Classification

What side effects are possible with Cla?

Possible Side Effects and Safety Information

The official safety profile for the Fixed-Dose Combination Cla (Amoxicillin, Clarithromycin, and Clavulanic Acid) is defined by categories of adverse reactions documented in regulatory sources such as the FDA and EMA. This profile outlines effects organized by frequency and the physiological system they impact.


Frequency and System-Organ Classifications

Adverse reactions are classified into categories reflecting how often they occur. Diarrhea is typically listed as a common gastrointestinal effect. Other effects are reported across various System-Organ Classes (SOC), including the Infections and Infestations (e.g., candidiasis), Nervous System (e.g., headache, dizziness), and Hepatobiliary (liver) systems.

Serious Adverse Reactions and Risk Patterns

The regulatory profile documents rare but clinically significant events. These include life-threatening severe hypersensitivity reactions (anaphylaxis) and severe dermatological conditions like Stevens-Johnson Syndrome (SJS). Safety information also notes the potential for hepatotoxicity, which can range from hepatitis to, in rare cases, hepatic failure. Furthermore, the macrolide component (Clarithromycin) is associated with the risk of QT interval prolongation and ventricular arrhythmia, including Torsades de Pointes.

Population-Specific Safety Constraints

Specific patient safety considerations are defined in official labeling. Use requires caution in patients with renal impairment, as adverse effects may be more pronounced. The medication is generally contraindicated in individuals with a history of cholestatic jaundice associated with prior use of the components, or in those with pre-existing QT prolongation. Official notes also describe that signs of hepatic events may have a delayed onset, sometimes appearing several weeks after treatment has concluded.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Cla (Amoxicillin, Clarithromycin, Clavulanic Acid) is based on the documented toxicological effects of its components and mandates immediate action for severe manifestations. Regulatory labeling confirms that overdose frequently presents with severe gastrointestinal symptoms, including stomach pain, vomiting, and diarrhea.

Documented Severe Outcomes

System Severe Manifestation (Documented in Regulatory Sources)
Cardiovascular Life-threatening arrhythmias, including QT prolongation and Torsades de pointes, are associated with the Clarithromycin component.
Neurological Risk of seizures (convulsions), particularly with high doses or in patients with impaired kidney function.
Hepatic/Renal Potential for fatal hepatic failure and acute renal failure due to crystalluria, especially from the Amoxicillin component.

Required Emergency Actions

The regulatory guidance states that medical assistance must be sought immediately if an overdose is suspected. Urgent medical care is required when the individual exhibits collapse, a seizure, difficulty breathing, or cannot be awakened. Management involves symptomatic and supportive measures, as no specific antidote is listed in the official prescribing information. The Amoxicillin and Clavulanic Acid components can be removed from circulation by hemodialysis.

Therapeutic Uses of Cla

The triple antimicrobial preparation, Cla (Amoxicillin, Clarithromycin, and Clavulanic Acid), is used for managing specific bacterial infections, focusing on conditions involving recurrent or episodic manifestations or resistance to standard single-agent therapy. Its use provides a supportive therapeutic benefit in addressing the underlying infection.

Main Uses and Therapeutic Benefit

Cla is applied across domains where additional symptomatic support is needed, primarily in the management of Helicobacter pylori infection (often associated with peptic ulcers), acute bacterial infections of the respiratory tract (such as Community-acquired Pneumonia), and complicated skin and soft tissue infections. This specialized therapeutic approach is commonly used to help with symptoms that may become intense or disruptive, including fever, persistent cough, acute pain, and chronic epigastric discomfort.

The benefit of this therapy is that it assists with maintaining functional stability during acute episodes and supports the patient through difficult manifestations. Treatment protocols are relevant when symptoms require a multi-faceted approach to symptom management. The medication supports the process of healing active peptic ulcers and helps maintain a sense of stability when infection symptoms are more noticeable.


Quick Fact: Relief for Resistant Symptoms

Cla is relevant in clinical settings that involve acute or unstable symptom patterns and is commonly used when pathogens are suspected of having resistance mechanisms, requiring a combination when short-term symptomatic assistance is needed.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Population Eligibility Rules for Cla

Official regulatory documentation defines clear rules for who can and cannot use the triple-agent medicine Cla (Amoxicillin, Clarithromycin, and Clavulanic Acid), based primarily on patient history, age, and organ health.

Absolute Contraindications

Use of Cla is prohibited for patients with a known hypersensitivity to any component (including penicillins and other beta-lactam antibiotics) or any history of severe hepatic dysfunction or cholestatic jaundice linked to prior use of the components. Cla is also strictly contraindicated for those with known QT prolongation, ventricular cardiac arrhythmias, uncorrected hypokalemia, or Infectious Mononucleosis.

Restricted and Conditional Use

Eligibility is restricted based on organ function and age. Patients with severe renal impairment (CrCl < 30 mL/min) or impaired hepatic function require special consideration. The tablet formulation is not recommended for children younger than 12 years or those weighing less than 40 kg. Use during pregnancy is not advised as safety has not been established, and caution is advised while breastfeeding due to excretion into milk. Certain forms must be avoided by patients with Phenylketonuria (PKU).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The combination preparation Cla has a documented interaction profile primarily driven by the Clarithromycin component’s effect as a potent inhibitor of the CYP3A4 enzyme and P-glycoprotein (P-gp) transporter, as stated in regulatory labels.

Formal Contraindicated Combinations

Co-administration is strictly contraindicated with several medicines due to the high risk of severe reactions caused by increased drug exposure. These prohibited combinations include the extensive CYP3A4-metabolized statins (Lovastatin and Simvastatin), which increase the risk of rhabdomyolysis. Also contraindicated are Ergotamine and Dihydroergotamine (risk of acute ergot toxicity), Oral Midazolam, and specific cardiovascular agents (Pimozide, Ticagrelor).

Pharmacokinetic and Pharmacodynamic Interactions

The Clarithromycin component may significantly increase the plasma concentration (AUC/Cmax) of numerous co-administered drugs metabolized by CYP3A4, such as Digoxin and Omeprazole. Conversely, strong CYP3A4 Inducers (e.g., Rifampicin, St John's Wort) may reduce Clarithromycin plasma levels.

The Amoxicillin component's interaction with Probenecid results in prolonged blood concentrations of Amoxicillin due to decreased renal tubular secretion. Co-administration with Oral Anticoagulants (e.g., Warfarin) may potentiate the prolongation of prothrombin time (INR), a pharmacodynamic effect documented in labeling.

Population and Procedural Constraints

One specific combination, Colchicine, is formally contraindicated only in patients with concurrent renal or hepatic impairment, reflecting a population-specific increase in interaction severity. Additionally, the Amoxicillin component may cause false-positive reactions in certain non-enzymatic urine glucose tests.

Mechanism of Action

The Integrated Antimicrobial Mechanism of Cla

The Cla combination utilizes a triple-action strategy focused on distinct molecular targets to initiate pathogen destruction. This mechanism is strictly peripheral and operates through two non-overlapping molecular pathways.

Simultaneous Cell Wall Destruction and Protein Synthesis Blockade

Amoxicillin acts as an irreversible inhibitor of bacterial Penicillin-Binding Proteins (PBPs), thereby halting the final assembly of the cell wall structure. Concurrently, Clarithromycin reversibly binds to the 50S ribosomal subunit, which blocks the synthesis of essential proteins and arrests the translocation of peptide chains. The resulting physiological effects are osmotic lysis (bacterial cell death) from the structural failure and growth arrest (stasis) from metabolic disruption.

Neutralization of Bacterial Defense Enzymes

The third component, Clavulanic Acid, is a mechanism-based suicide inhibitor that targets and neutralizes beta-Lactamase enzymes, which resistant bacteria utilize to inactivate Amoxicillin. By eliminating this defense, Clavulanic Acid supports the persistence of the primary cell-wall-disruption mechanism against beta-Lactamase-producing bacteria, thus broadening the range of susceptible pathogens.

Dosage and Administration Information

The Cla combination therapy is exclusively administered via the oral route, utilizing the specific doses of Amoxicillin, Clarithromycin, and a Proton Pump Inhibitor (PPI) packaged together for ease of adherence. This standardized regimen is designed for a fixed, short-term treatment course and is characterized by precise usage protocols.

The therapy is typically administered as a full combination dose taken twice daily (BID), generally separated by 12 hours, such as once in the morning and once in the evening. To ensure appropriate administration, the full dose of capsules and tablets should be taken before eating a meal. The individual components in the daily regimen must be swallowed whole with water, and are not intended to be crushed, split, or chewed, as this could compromise the integrity of the delivery system. The entire course typically lasts for a specified duration, generally 10 to 14 days, and must be completed in its entirety.

Standard protocols include considerations for specific patient populations. For individuals with severe renal impairment (creatinine clearance below 30 mL/min), a reduced dosage of the Clarithromycin component is recommended to accommodate altered drug clearance. If a dose is missed, it is generally advised to take it as soon as possible, unless it is almost time for the next scheduled dose, in which case the missed dose must be skipped. Patients must not double the dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cla

This section describes the structure of the research that has explored the use of Cla (Amoxicillin, Clarithromycin, and Clavulanic Acid) for specific bacterial infections. It outlines the types of studies conducted and what outcomes they monitored, without stating or implying any personal benefits or making clinical recommendations.

Evidence for Use in extitHelicobacter pylori Infection and Peptic Ulcers

Research was studied for this combination in conditions characterized by fluctuating or episodic manifestations, such as extitH. pylori infection, which is often associated with peptic ulcers. The evidence base includes pharmacological studies that examined the strategic combination and its reported effect, alongside information derived from clinical consensus guidelines and clinical recognition documents.

Studies primarily measured outcomes related to the eradication of pathogenic bacteria over defined time intervals. Researchers also monitored outcomes reflecting systemic imbalance, such as outcomes linked to inflammatory or irritative states and tracked processes related to ulcer healing. Research explored how symptoms evolved in the observed populations, and studies monitored outcomes related to physical discomfort.

Evidence for Use in Acute Bacterial Infections (Respiratory and Skin)

Research examined these uses, focusing on patients with conditions involving periods of heightened symptoms or where the infection was suspected of having resistance mechanisms. Studies explored measures related to pathogenic bacteria eradication and research described the specific combination strategy where a shielding effect was observed. Research also monitored outcomes reflecting systemic or functional imbalance, including fever, persistent cough, and acute pain, and studied outcomes related to daily functioning or activity level during the study period.

What Research Remains Unclear or Limited

The primary limitation across the evidence landscape is the limited information for long-term outcomes, as follow-up durations were limited in studies focusing on acute or disruptive episodes. Long-term effects are not fully established, and data for certain groups remain insufficient. Furthermore, comparative evidence is lacking in the provided summaries regarding how this specific triple combination formulation was evaluated in versus other alternative anti-infective regimens that may be used for the same indications.

Key Studies & References

  1. Amoxicillin; Clarithromycin; Clavulanic Acid (Fixed Dose Combination) - NIH Bookshelf
  2. Amoxicillin, Clarithromycin, and Clavulanic Acid Fixed-Dose Combination Drug Information - NIH MedlinePlus

Frequently Asked Questions (FAQ)

Common questions about Cla (FAQ)


Q: What happens if I stop taking Cla suddenly?

Regulatory instructions state that the prescribed treatment course should be completed in its entirety. Stopping the medication before the course is finished, even if symptoms improve, may increase the risk of the original infection not being completely cleared, potentially leading to treatment failure.


Q: How quickly do people generally notice the effects of Cla?

Studies and official information indicate that for some acute infections, changes may be observed in the initial days of treatment. However, for certain conditions, such as H. pylori infection, it can take longer for symptoms to fully resolve, even after the entire course is finished.


Q: Is Cla a commonly used medicine for its approved purpose?

The strategy used by Cla, which involves combining antibiotics with different ways of fighting bacteria, is a clinically established method. This approach is often favored in clinical consensus guidelines to maximize the successful clearing of specific, particularly resistant, infectious diseases.


Q: Can Cla cause changes in sleep patterns?

The official safety profile reports that one of the components, Clarithromycin, includes insomnia (difficulty sleeping) as a documented adverse reaction. Patients are generally advised to discuss any concerning changes, such as persistent sleep issues, with a healthcare professional.


Q: Is it true that Cla can interact with certain foods?

Official usage protocols specify that the full dose of capsules and tablets should be taken before eating a meal. This instruction is provided in the label to ensure appropriate administration of the drug regimen.


Q: What are the most common mild side effects reported for Cla?

According to regulatory documents, the most frequently reported common side effects include gastrointestinal effects such as abdominal pain, diarrhea, nausea, and vomiting. Some patients also report changes in their sense of taste, known as dysgeusia.


Q: How is Cla different from other medicines used for the same condition?

Cla is designed as a specific Fixed-Dose Combination (FDC) preparation. This means it bundles two different types of antibiotics (Amoxicillin and Clarithromycin) and a protective agent (Clavulanic Acid) into a single regimen, representing a targeted approach to enhance efficacy against resistant bacteria.


Q: Does Cla need to be taken at a specific time of day?

Official drug documents specify that the full combination dose must be taken twice daily (BID), with approximately 12 hours separating the doses. A typical schedule described in the regulatory information is once in the morning and once in the evening.


Q: Can Cla affect the way certain lab tests are measured?

Yes, official information notes that the Amoxicillin component may cause false-positive reactions in certain laboratory tests, specifically non-enzymatic urine glucose tests. It is generally advised that patients inform healthcare providers about all medicines they are taking before any laboratory tests.


Q: Is there a maximum length of time people typically take Cla?

This regimen is designed as a fixed, short-term treatment course for acute infections. The specified duration of treatment typically lasts 10 to 14 days, as outlined in official prescribing information for its approved uses.


Q: What are the signs of a serious, but rare, side effect of Cla?

The safety profile describes potential signs of rare, serious liver reactions (hepatotoxicity) as including persistent loss of appetite, yellowing of the skin or eyes (jaundice), dark urine, or tenderness in the abdominal area. These descriptions are derived from regulatory documents.


Q: Is it possible to be allergic to Cla?

Yes. According to regulatory guidelines, Cla is prohibited (contraindicated) for patients with a known hypersensitivity or allergy to any of its components, including the penicillin type of antibiotics. Patients experiencing signs that suggest an allergic reaction are typically directed to seek emergency care.


Q: Are there different strengths or formulations of Cla available?

The primary combination is available as oral tablets or capsules. However, official drug information also details the use and stability of separate reconstituted liquid suspensions for the Amoxicillin/Clavulanate and Clarithromycin components, which may be prescribed.


Q: Is it normal to feel tired or dizzy when starting Cla?

The official safety profile reports side effects like dizziness, headache, and general fatigue or asthenia as documented adverse reactions. These effects are documented in the safety profile, and official patient information notes that they may occur, particularly at the start of treatment.


Q: Does Cla interfere with birth control pills?

Official information notes that severe gastrointestinal issues, such as vomiting or diarrhea, which are common side effects of the antibiotic component, are associated with a potential for reduced contraceptive protection.


Q: Can using alcohol while on Cla increase the side effects?

Official drug information suggests that although there is no formal drug-alcohol contraindication, consuming alcohol may increase the occurrence or perceived severity of common gastrointestinal side effects such as nausea, vomiting, and diarrhea.


Q: Is it safe to get a vaccine while taking Cla?

Information from public health agencies indicates that treatment with antibiotics, including the components of Cla, is generally not considered a reason to delay the administration of a vaccine. Vaccination is typically only deferred if the patient has a moderate or severe acute illness.


Q: Is Cla known to be habit-forming?

No. Cla is classified as an Antibiotic/Antimicrobial Combination Regimen by regulatory bodies. It is not listed as a controlled substance with potential for abuse or dependence.


Q: Can Cla be taken with supplements or vitamins?

Official labeling states that the full list of potential interactions includes certain supplements. For example, official drug labels note that certain supplements, such as St John's Wort, may interact and lead to altered levels of one of the components.


Q: Can taking Cla affect my ability to drive or operate machinery?

Side effects that affect the nervous system, such as dizziness or headache, are listed in the official safety profile. These effects may impact an individual’s ability to drive or operate machinery, and official patient information often describes a need for caution when performing activities that require full alertness.


Q: What happens if I accidentally take too much Cla?

Official instructions describe the protocol in the event of an accidental overdose as seeking emergency medical attention immediately or contacting a Poison Help line. This guidance is provided in the official drug label.

How should Cla be stored and disposed of?

How to Store and Dispose of Cla (Amoxicillin, Clarithromycin, and Clavulanic Acid)

The official storage conditions for Cla are defined by the medication's form. Tablets and capsules must be stored at controlled room temperature and protected from excess heat and moisture. The medication must be kept in its tightly closed original container and stored out of the sight and reach of children.

Form-Specific Storage and Stability

Medication Form Temperature Requirement Stability Limit
Amoxicillin/Clavulanate Suspension (Reconstituted) Must be refrigerated Discard after 10 days
Clarithromycin Suspension (Reconstituted) Must not be refrigerated Discard after 14 days

Unused or expired product should be disposed of using an authorized drug take-back option. If unavailable, the medicine should be mixed with an unappealing substance, sealed in a plastic bag, and placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cla found in:

A-Z Index: